At the Aging Research and Drug Discovery meeting at Harvard, Novo and Eli Lilly presented early data applying aging biomarkers to GLP-1 receptor agonists. Novo modeled a 1.9-year gain in remaining life expectancy from SELECT trial estimates in a UK semaglutide cohort and reported lower proteomic biological age within 13 to 20 weeks; Lilly's epigenetic sub-study of tirzepatide in SURMOUNT-5 found all 15 epigenetic clocks registering less aging than the 1.38 years elapsed, with two reaching statistical significance. Both companies framed the work as preliminary method validation rather than definitive evidence.
Key Points
- Semaglutide modeling projects 1.9 additional life-years, largest at younger ages
- All 15 epigenetic clocks showed tirzepatide aging below chronological time
- Organ clocks indicated lower predicted immune, kidney, liver, cardiovascular age
Longevity Analysis
Metabolic drugs are now being evaluated on the same instruments the aging field uses to assess intervention — methylation clocks, pace-of-aging measures, proteomic signatures — which moves the conversation from weight and glycemic endpoints toward how fast tissues deteriorate. The organ-specific signals in immune, kidney, liver and cardiovascular readouts are consistent with reduced inflammatory load and improved metabolic signaling, though sample sizes of 71 to 82 paired subjects and modeled life expectancy gains cannot establish causation. For clinicians, the practical value lies in the measurement approach itself: tracking biological age trajectories over time offers a more sensitive read on whether any intervention is changing the underlying rate of decline rather than a single downstream marker.
Original published by Longevity.Technology, by Phil Newman.